Navigation Links
New treatment to overpower drug resistance in ovarian cancer
Date:11/15/2010

Drug resistance is a major obstacle in curing ovarian cancer but new research from the Centenary Institute has discovered a treatment that kills ovarian cancer cells in a new way that can break the resistance mechanism. Published today in Autophagy, the researchers found the drug (FTY720) had a potent effect in human ovarian cancer cells, even in those resistant to cisplatin, the most commonly used chemotherapeutic drug currently available for the treatment of ovarian cancer.

Centenary Institute Signal Transduction Head Associate Professor Pu Xia described the findings as a breakthrough in ovarian cancer treatment because, FTY720 kills ovarian cancer cells through a unique way different to the current anti-cancer drugs. Current treatments, such as cisplatin, kill ovarian cancer cells through a way of programming cell death known as apoptosis but this is often reversible or demolished by cancer cells. However, FTY720 kills cells through an irreversible process known as necrosis so the cancer cells cannot resist, repair and relapse.

Each year, around 800 Australian women die from ovarian cancer1, and ovarian cancer remains the leading cause of death in women with gynaecological malignancies over the world.

Dr Xia said: "One of the major reasons for such a poor outcome of ovarian cancer is that the cancer cells have an ability to resist the current chemotherapeutic drugs through a protective shield, which occurs naturally or as a response to the treatment, and this survives the cancer from the treatment. Such a protective shield, uncovered by the findings from the Xia laboratory, is built, at least partially, on a catabolic process, called autophagy, by which cells eat their own non-vital components for survival under stress conditions such as starvation or chemotherapy. Remarkably, despite this survival process being activated by ovarian cancer cells during the treatment, FTY720 is still capable of killing them effectively. '/>"/>

Contact: Tanya Sarina
t.sarina@centenary.org.au
61-295-656-228
Centenary Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. Breast cancer treatment resistance linked to signaling pathway
2. The dietary supplement genistein can undermine breast cancer treatment
3. Coming soon: Self-guided, computer-based depression treatment
4. Nanodiamond drug device could transform cancer treatment
5. Disinfectants can make bacteria resistant to treatment
6. Scientists from Granada find a potential treatment to prevent diabetes and obesity
7. FSU researchers discovery leads to $1.5 million grant, potential new treatment of liver fibrosis
8. Researchers at National Jewish Health evaluating a treatment
9. National Jewish Health researchers evaluating treatment to help emphysema sufferers breathe easier
10. First comprehensive genomic study of common cold reveals new treatment targets
11. Iowa State researcher develops new treatment method for canine eye diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2015)... Aug. 19, 2015  VOXX International Corporation (Nasdaq: ... entered into a Definitive Agreement to purchase the ... authentication market leader EyeLock through an acquiring entity.  ... a controlling interest in the acquiring entity. The ... of due diligence.  Expanding on its existing supply ...
(Date:8/18/2015)... , Aug. 17, 2015 Research and ... of the "Global Biometric Authentication & Identification ... Estimation & Forecast, 2015-2020" report to their ... and identification systems market is expected to grow ... to 2020 and generate over $25 billion (approximately) ...
(Date:8/12/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is proud to announce that ... eClinical technology platform, has led the way to significant ... of 2015.   Q2 2015 and Q1 2015 were, ... contract value sold in the company,s 15 year history.  ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2MedNet Solutions Experiences Explosive Corporate Growth 2
... in 1971 and have become a leading international forum ... and biocatalysis, putting an emphasis on emerging technologies and ... The proposed scope and thrust of the conference will ... developments in fields including protein design and computation, catalytic ...
... - Adrenaline, the hormone that prepares our body to ... molecule switches so fast between several positions, that it ... Jan Steyaert of VIB and the Vrije Universiteit Brussel ... US, have "frozen the molecule in action" using Xaperones, ...
... In the late 1950s, Richard Feynman famously imagined a ... by manipulating matter and creating structures all the way ... over fifty years after "There,s Plenty of Room at ... Angela Belcher, Donald Eigler, and Michael Roukes - are ...
Cached Biology News:Adrenaline receptor 'frozen in action' by VIB researchers 2Scaling up: The future of nanoscience 2Scaling up: The future of nanoscience 3
(Date:9/2/2015)... Virginia , September 2, 2015 ... der Gewinner des Wettbewerbs BeHEARD von 2015 bekanntgeben ... internationalen vom Rare Genomics Institute. Biovista ... von Medikamenten für die Behandlung anderer Krankheiten als ... Steven Laffoon und sein Team bei ...
(Date:9/2/2015)... ... 2015 , ... Whitehouse Laboratories is excited to announce that ... upcoming educational seminar and training session on Extractable & Leachable testing. Featuring a ... Updates & Case Studies on the Latest Compliance Implications of USP and ICH ...
(Date:9/2/2015)... ... September 02, 2015 , ... The ... creating professional commercial video content, to analysis of athletic performance. Producing high-resolution ... go by too quickly to process with the naked eye. , Slow ...
(Date:9/1/2015)... , September 2, 2015 ... primär auf die Forschung und Entwicklung neuartiger ... Allergien, chronisch-entzündliche Darmerkrankungen und Reizdarm konzentriert, erhält ... Zusage, dass sein neues Medikament patentiert wird. ... das Allergien bei Kindern verhindert und Entzündungen ...
Breaking Biology Technology:Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 2Fastec Introduces the Quad-HD TS5-Q High-Speed Camera 3Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2
... PALO ALTO, Calif. , May 4 "BIO has ... of the biotechnology sector.  It is my goal to build upon these ... fosters the right policy environment for the biobased solutions that our industry ... , , ...
... GENEVA, SWITZERLAND , May 4 /PRNewswire-FirstCall/ - Anavex Life ... from animal studies with ANAVEX 2-73, the company,s lead compound for ... , , ... a new class of drugs that target mitochondrial dysfunction thought to ...
... which have four triangular sides, pack more densely than ... by a collaboration of New York University and Virginia ... series of experiments that involved pouring tetrahedral dice into ... containers were completely filled. After adding water to measure ...
Cached Biology Technology:Statement from Genencor CEO Tjerk de Ruiter Upon Being Elected as Chair of the Industrial & Environmental Section and Board of Directors of the Biotechnology Industry Association (BIO) 2Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials 2Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials 3Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials 4Anavex reports animal study results as lead Alzheimer's compound approaches phase 1 clinical trials 5Densest dice packing and computing with molecules 2
Any form, any size, any number of mutageneses. ExonBio provides the best service with double sequecing to make sure the success of the mutagenesis....
Loading Buffer...
Request Info...
Request Info...
Biology Products: